The Creative Antibody Solutions Company
Simple. Innovative. Solutions
Antibody therapies, particularly in cancer have been revolutionary. We have made great strides in treating patients, however this is limited to 20-30% of all patients. Solid tumour antibody penetration and toxicity are still the biggest barriers.
CreaTap is the patented Creasallis Tumour Antibody Penetration technology that improves the penetration of antibody-based drugs into the tumour. It is a single plug-and-play technology, which means it can be incorporated into any existing antibody. Creasallis has also started to build capabilities to build its own suite of antibody therapeutics with enhanced penetration.
Monoclonal antibodies for solid tumours can be easily modified into CreaTap versions to improve their penetration into the tumour. These could include checkpoint antibodies that need to reach immune cells imbedded deeper into the tumour.
Delivering the cytotoxic payload deeper into the tumour is vital for killing all cancer cells in antibody drug conjugates. The CreaTap technology can be used to achieve that deeper penetration, killing more cells.
The CreaTap technology could be modified for bispecific antibodies. If you have a bispecific antibody that would benefit from being able to penetrate the tumour deeper, Creasallis could attempt to re-engineer them to improve penetrability.
The CreaTap technology can be extended outside of the scope of antibodies to any protein/pepetide conjugates that would benefit from deeper penetration. Speak to our expert team of engineers to disucss this further.
Beyond improving drug penetration, incorporation of the CreaTap technology into existing protein based drugs can open new opportunities to patent the drug product. Work with Creasallis to protect your products for longer.
The CreaTap technology is a modification of the an antibody to enable it to enter the tumour micro environment and penetrate the tumour deeper. We have adapted the technology so it can be applied to any antibody isotype, making it a single plug and play technology.
Creasallis was founded in 2021 by Zahra Jawad. It was created after the realization that innovation is limited in the pharmaceutical industry as the product pipeline dominates in this environment, and competition for resourcing and facilities is high. To make truly innovative drugs, start ups are needed to create that safe space to explore novel solutions.
in the biopharmaceutical industry, with over 20 years experience developing antibody-based therapeutics, building teams and implementing engineering solutions to antibody bottlenecks. The team has extensive experience working at large pharmacuetical companies and biotechs such as Domantis, GSK, Lonza, Abzena, Monte Rosa, Agenus and MRC-Technology. Our expert team has worked in industry and have developed and run pipelines in antibody discovery, expression and analytics.
Antibody drug penetration into the tumour is very low, estimated to be between 0.001-7%. The large size of biological macromolecules like antibodies mean their diffusion is limited through the tumour. If more of the antibody drug can penetrate into the tumour, then patients with later stage cancer could be treated, or lower doses of drug can be administered.
At the heart of our philosophy is simple solutions for antibody engineering bottlenecks. This is why we have designed the CreaTap technology to be a universal solution of all protein based therapeutics. Our solution is a single modification that can be applied to all biologics, therefore we do not need a new discovery process when modifying antibodies. This ensures that we can help you reach IND as quickly as possible.
Expert team of antibody engineers with world-class biotech and pharma experience
Technology applicable to all oncology-based antibodies with a single plug-and-play solution
Simple manufacturing process
Patentable technology that would increase exclusivity rights on existing antibodies